AstraZeneca/Oxford say Covid vaccine shows 70% efficacy, can be 90% effective
"This vaccine's efficacy and safety confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency," AstraZeneca chief executive Pascal Soriot said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark
The Phase 3 study with Favipiravir, sold under the brand name FabiFlu, by the company was conducted in 150 patients, it added. Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy, Glenmark said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Covid-19 vaccine: Oxford trials show 70 per cent efficacy
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca will have 200 million COVID vaccine doses by year-end
Its operations executive Pam Cheng told a briefing that there would be 20 million doses in Britain by the end of the year, with 70 million doses for the UK by the end of Q1 2021. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus
Speaking in a briefing, Andrew Pollard, director of the Oxford Vaccine Group, said it is hard to explain the different efficacy rates between the AstraZeneca/Oxford shot and the other vaccines developed by Pfizer and BioNTech and one by Moderna. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Post trial results, AstraZeneca CEO says smaller first dose in COVID-19 vaccine is 'big plus'
The British drugmaker said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Some signs AstraZeneca vaccine durability could be a year: Chief investigator
"We don't know yet if this virus will be mutating away from the immune response," the Oxford vaccine group's director Andrew Pollard told reporters at a briefing, adding: "There is no evidence of that yet." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Covid-19 vaccine distribution faces logistics, supply chain challenges, says expert
While the government would do its job on procurement and distribution, the focus should be on keeping the spread under check and studying the virus for having more effective antiviral drugs till a vaccine was available, Dr Rakesh Mishra, Director of CSIR-Centre for Cellular and Molecular Biology (CCMB) said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 22, 2020 Category: Pharmaceuticals Source Type: news

Government to provide industrial park facilities to grow API, pharma & nutraceutical industry
Indian pharma industry will continue to play a prominent role as the pharmacy of the world, the Chemicals and Fertilizers Ministry said in a statement. In his message to an international pharmacist webinar on National Pharmacy Week, he said that the government is sensitive to grievances of pharmacists and is committed to improving a lot of pharmacists. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 22, 2020 Category: Pharmaceuticals Source Type: news

Moderna to charge $25-$37 for COVID-19 vaccine: CEO
On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 22, 2020 Category: Pharmaceuticals Source Type: news

Sukoon Health to invest over Rs 100 cr to open 4 health centres by 2023-end
The company currently has a tie up with Fortis Healthcare for its Gurugram-based super specialty hospital which has three psychiatric ICUs. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 22, 2020 Category: Pharmaceuticals Source Type: news

Astra-Oxford shot is key to escaping pandemic for many nations, including India
The Astra vaccine costs a fraction of the price set by Pfizer and will be manufactured in multiple countries, from India to Brazil. It should be easier to deploy far and wide than other shots that need to be stored at ultra-cold temperatures. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 22, 2020 Category: Pharmaceuticals Source Type: news

Bharat Bio trials went on despite adverse effect; experts worried
A participant in phase 1 clinical trials of the Covid vaccine being developed by Bharat Biotech in collaboration with Indian Council of Medical Research (ICMR) fell ill and had to be hospitalised after taking the shot in July, but the trials were not halted and no public disclosure was made. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 21, 2020 Category: Pharmaceuticals Source Type: news

India's Bharat Biotech offers Brazil potential COVID-19 vaccine
The private pharmaceutical company based in the southern city of Hyderabad is developing a whole-virion inactivated vaccine called Covaxin that could be licensed by the second quarter of 2021. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 20, 2020 Category: Pharmaceuticals Source Type: news

Delay in vaccine availability likely as India banks only on local makers
India has the capacity and tie-ups to manufacture about 2 billion vaccine doses but its strategy to bank only on local production and not enter into any pre-purchase agreements with multiple global drugmakers could delay the availability of vaccines in the country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 20, 2020 Category: Pharmaceuticals Source Type: news

Serum Institute's Adar Poonawalla expects every Indian to be vaccinated by 2024
Speaking at a media event, Poonawalla said the Oxford AstraZeneca Covid-19 vaccine should be available for healthcare workers and elderly people by February 2021 and by April for the general public. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 20, 2020 Category: Pharmaceuticals Source Type: news

Pfizer seeking emergency use of its COVID-19 vaccine in US
The action comes days after Pfizer Inc and its German partner BioNTech announced that its vaccine appears 95 per cent effective at preventing mild to severe COVID-19 disease in a large, ongoing study. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 20, 2020 Category: Pharmaceuticals Source Type: news

First animal study in India on coronavirus moves to its final stage, says AYUSH Ministry
The clinical studies are being pursued through another collaboration of the Ministry of AYUSH, the partner in this one being the Council for Scientific and Industrial Research (CSIR). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 20, 2020 Category: Pharmaceuticals Source Type: news

Pfizer seeks emergency use of its Covid-19 vaccine in US, looks at starting process in Decemeber
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 20, 2020 Category: Pharmaceuticals Source Type: news

Pfizer-BioNTech vaccine deliveries could start 'before Christmas'
The vaccine's efficacy was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately hurt the elderly and certain groups including Black people. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 19, 2020 Category: Pharmaceuticals Source Type: news

Dr Reddy's starts detailed investigation into anonymous complaint
"Dr Reddy's Laboratories has commenced a detailed investigation into an anonymous complaint. The complaint alleges that healthcare professionals in Ukraine and potentially in other countries were provided with improper benefits in violation of US laws," the company said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 19, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca COVID-19 shot candidate shows promise among elderly in trials
The data, reported in part last month but published in full in The Lancet medical journal on Thursday, suggest that those aged over 70 - who are at higher risk of serious illness and death from COVID-19 - could build robust immunity to the pandemic disease, researchers said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 19, 2020 Category: Pharmaceuticals Source Type: news

Coronavirus pandemic is the catalyst to speed up technological changes, says Anand Mahindra
"The crisis has shaken up the way we view the world and exposed the fault lines in our society. It has also emphasised the necessity for quick and relevant solutions for the new world that is rising from the ashes of the old," said Mahindra. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 19, 2020 Category: Pharmaceuticals Source Type: news

Govt pins hopes on 5 Covid shots under trial in India
Niti Aayog member Dr V K Paul, who also heads the national expert group on vaccine administration, said all these vaccines were on easy platforms and availability of adequate doses as per India ’s requirement was also assured. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 18, 2020 Category: Pharmaceuticals Source Type: news

Cipla inks licensing deal with Belgium's MultiG for distribution of COVID-19 antibody test kit
"As part of this agreement, Cipla will be responsible for distribution of the COVID-19 rapid antibody kit that will be manufactured by MultiG" the company added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 18, 2020 Category: Pharmaceuticals Source Type: news

Protein-based COVID-19 vaccine candidates would be more suitable for India, scientists say
The decision on procuring the right COVID-19 vaccine depends on multiple factors, including safety, price and ease of deployment, the scientists added, pitching for a preventive like the one being developed by US firm Novavax that can be stored at lower temperatures rather than those developed from mRNA or viral vectors. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 18, 2020 Category: Pharmaceuticals Source Type: news

Coronavirus vaccine development is on track. The next challenge? Tackling the side effects
The U.S. Centers for Disease Control and Prevention plans to send daily texts to those who are vaccinated for the first week and then weekly texts for six weeks, while the Food and Drug Administration will also be monitoring side effects in real time. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 18, 2020 Category: Pharmaceuticals Source Type: news

Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 18, 2020 Category: Pharmaceuticals Source Type: news

Pfizer claims final trials of Covid-19 vaccine 95 per cent effective
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 18, 2020 Category: Pharmaceuticals Source Type: news

Bharat Biotech begins Phase-III trials for COVID-19 vaccine, Covaxin, with 26,000 volunteers
"This is India's first phase-III efficacy study for a Covid-19 vaccine, and the largest phase-III efficacy trial ever conducted in India," said Bharat Biotech in a statement on Monday, adding that the trial was registered at ICMR and approved by the Drugs Controller General of India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 17, 2020 Category: Pharmaceuticals Source Type: news

Biological E gets DGCA nod to begin the next phase of trials for its COVID-19 vaccine
This vaccine candidate includes an antigen that was in-licensed from BCM Ventures, which is an integrated commercialisation team of Baylor College of Medicine in Houston, and an advanced adjuvant from the US-based vaccine focused pharmaceutical firm Dynavax Technologies Corporation. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 17, 2020 Category: Pharmaceuticals Source Type: news

ADB allocates $20 million to help developing member nations access vaccines for COVID-19
Funds will help members assess and strengthen vaccine cold chain and logistics, infection control, supply and skills of health workers, risk communications, and real-time data capturing and monitoring, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 17, 2020 Category: Pharmaceuticals Source Type: news

Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug
In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the US Food and Drug Administration (FDA) seeking approval to market generic versions of Ibrance. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 17, 2020 Category: Pharmaceuticals Source Type: news

India pins hopes on locally-tested COVID-19 vaccines given Pfizer constraints
The five candidates include Russia's Sputnik-V whose "Phase-II going to Phase-III" trials in India will start next week in collaboration with Dr Reddy's Laboratories, Vinod Paul, the head of a committee advising the prime minister, said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 17, 2020 Category: Pharmaceuticals Source Type: news

Coronavirus Vaccine: Moderna says its COVID-19 shot is nearly 95% effective
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 16, 2020 Category: Pharmaceuticals Source Type: news

India in dialogue with Moderna, other biotech firms over progress in COVID vaccine development: Sources
Moderna on Monday said the independent National Institutes of Health-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, found the vaccine to have an efficacy of 94.5 percent. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 16, 2020 Category: Pharmaceuticals Source Type: news

India's pharmaceutical market posts 10% growth in October
The revival was on the back of therapies, including cardiac and anti-diabetic, which grew by 19.5% and 9.7% respectively in October (over September), according to data from research firm AIOCD Awacs. Respiratory medicines showed marginal improvement at -6.6% in October as against -10.5 % in September. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 16, 2020 Category: Pharmaceuticals Source Type: news

Covid vaccine: Inching closer to a cure
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 16, 2020 Category: Pharmaceuticals Source Type: news

Healthcare brand Vize ropes in Virat Kohli as the Brand Ambassador
Vize has introduced hand sanitizer gel, sprays, liquid cans, antiseptic liquids, mobile cleansing spray, set of sanitizing wet wipes and air freshener sanitizer spray at the launch. The products will be available through digital distribution via Flipkart, Amazon and PharmaEasy. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 16, 2020 Category: Pharmaceuticals Source Type: news

Bharat Biotech's COVID-19 vaccine "Covaxin" enters phase-3 trials
Speaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 16, 2020 Category: Pharmaceuticals Source Type: news

First batch of Sputnik V vaccine to arrive in Kanpur medical college for Phase 2, 3 trials
The decision to conduct the human clinical trials of the vaccine was taken after Dr Reddy's Laboratories got approval from the Drugs Controller General of India (DCGI) in this regard, an official said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 15, 2020 Category: Pharmaceuticals Source Type: news

Steroid treatment should be reserved for sickest COVID-19 patients, say scientists
Scientists, including those from St. Jude Children's Research Hospital in the US, assessed the levels of the immune system protein cytokines, and other health markers in 168 adults with COVID-19, 26 adults with flu and 16 healthy volunteers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 15, 2020 Category: Pharmaceuticals Source Type: news

Indian drug firms recall various products in US market
While Marksans Pharma is recalling diabetes drug, Zydus Pharmaceuticals (USA) is recalling drug which is used to reduce stomach acid. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 15, 2020 Category: Pharmaceuticals Source Type: news

IIT Roorkee scientists predict FDA-approved commercial drugs through AI to tackle COVID-19
Amid the rapid transmission of cases of Covid-19, a group of scientists from IIT Roorkee has leveraged Artificial Intelligence (AI) to predict 10 FDI (Food and Drug Administration) approved commercial drugs available for the treatment of the disease. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 13, 2020 Category: Pharmaceuticals Source Type: news

Natco Pharma's marketing partner gets USFDA nod for cancer treatment drug
​​ "Breckenridge Pharmaceutical Inc. has received final approval for its abbreviated new drug application (ANDA) for Pomalidomide Capsules from the US Food and Drug Administration (USFDA)," Natco Pharma said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 13, 2020 Category: Pharmaceuticals Source Type: news

India to get 100 million AstraZeneca's Covid vaccines next month: Serum Institute head
If final-stage trial data show AstraZeneca ’s candidate gives effective protection from the virus, the Serum Institute of India Ltd. -- which is partnered to produce at least one billion doses -- may get emergency authorization from New Delhi by December, said Adar Poonawalla. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 13, 2020 Category: Pharmaceuticals Source Type: news

Serum says made 40 mn doses of AstraZeneca's COVID vaccine, to make Novavax shot soon
Serum said it has enrolled 1,600 participants in India for late-stage trials of AstraZeneca's candidate, and also plans to seek regulatory approval to run late-stage trials for the Novavax vaccine. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 12, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca's cancer drug fails to meet main goal in COVID-19 trials
The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its COVID-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 12, 2020 Category: Pharmaceuticals Source Type: news

Lupin, Concord Biotech get USFDA nod for generic immunosuppressant capsules
In alliance with Concord Biotech, the company has received approval from the United States Food and Drug Administration (USFDA) to market Tacrolimus capsules USP, in the strengths of 0.5 mg, 1 mg, and 5 mg, Lupin said in a filing to the BSE. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 12, 2020 Category: Pharmaceuticals Source Type: news

Pfizer starts talks with Covax facility for equitable distribution of COVID-19 vaccine
The company is in discussions with the Gavi vaccine alliance to potentially provide doses to the Covax facility, a Pfizer spokesperson told ET, adding: "It is our intention to achieve equitable global distribution of vaccine supply in alignment with identified priority populations." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 12, 2020 Category: Pharmaceuticals Source Type: news